Earnings summaries and quarterly performance for Whitehawk Therapeutics.
Executive leadership at Whitehawk Therapeutics.
Board of directors at Whitehawk Therapeutics.
Research analysts covering Whitehawk Therapeutics.
Recent press releases and 8-K filings for WHWK.
Whitehawk Therapeutics Advances Two ADC Programs to Clinical Stage
WHWK
Product Launch
New Projects/Investments
- The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for HWK-007, Whitehawk's PTK7-targeted antibody-drug conjugate (ADC), with its Phase 1 trial now actively recruiting for lung, ovarian, and endometrial cancers.
- Whitehawk also submitted an IND for HWK-016, its MUC16-targeted ADC, in December 2025, with a Phase 1 trial anticipated to start this quarter (Q1 2026) for ovarian and endometrial cancers.
- The company expects to report initial clinical data from both HWK-007 and HWK-016 trials in early 2027.
Jan 8, 2026, 1:00 PM
Whitehawk Therapeutics, Inc. Reports Q3 2025 Financial Results and Operational Progress
WHWK
Earnings
Guidance Update
New Projects/Investments
- Whitehawk Therapeutics, Inc. reported a net loss of $17.7 million for the third quarter ended September 30, 2025, compared to a net loss of $12.5 million for the same period in 2024.
- The company's cash, cash equivalents, and short-term investments totaled $162.6 million as of September 30, 2025, an increase from $47.2 million as of December 31, 2024. This cash position is anticipated to fund operations into 2028.
- Whitehawk Therapeutics is on track for Investigational New Drug (IND) submissions for HWK-007 and HWK-016 by year-end 2025, with an IND for HWK-206 expected by mid-2026.
Nov 6, 2025, 1:03 PM
Whitehawk Therapeutics Reports Q3 2025 Financial Results and Pipeline Progress
WHWK
Earnings
Guidance Update
New Projects/Investments
- Whitehawk Therapeutics reported a net loss of $17.7 million for the third quarter ended September 30, 2025, compared to a net loss of $12.5 million for the same period in 2024.
- As of September 30, 2025, cash, cash equivalents, and short-term investments totaled $162.6 million, an increase from $47.2 million as of December 31, 2024, with capital anticipated to fund operations into 2028.
- The company is on track to file Investigational New Drug (IND) applications for HWK-007 and HWK-016 by year-end 2025, and for HWK-206 by mid-2026.
Nov 6, 2025, 1:00 PM
Quarterly earnings call transcripts for Whitehawk Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more